212 related articles for article (PubMed ID: 2342588)
1. Combination and single-agent empirical antibacterial therapy for febrile cancer patients with neutropenia and mucositis.
Shenep JL
NCI Monogr; 1990; (9):117-22. PubMed ID: 2342588
[TBL] [Abstract][Full Text] [Related]
2. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
Jarque I; Sanz MA
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
[TBL] [Abstract][Full Text] [Related]
3. Empiric single agent or combination antibiotic therapy for febrile episodes in neutropenic patients: an overview.
Lieschke GJ; Bell D; Rawlinson W; Green MD; Sheridan W; Morstyn G; Stuart-Harris R; Kefford RF; Levi J; Sorrell T
Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S37-42. PubMed ID: 2693108
[TBL] [Abstract][Full Text] [Related]
4. Monotherapy for empirical management of febrile neutropenic patients.
Rubin M; Pizzo PA
NCI Monogr; 1990; (9):111-6. PubMed ID: 2160613
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada-Clinical Trials Group.
J Infect Dis; 1991 May; 163(5):951-8. PubMed ID: 2019772
[TBL] [Abstract][Full Text] [Related]
6. Empirical antibiotics for febrile neutropenic cancer patients.
Hathorn JW
Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S43-51. PubMed ID: 2693109
[TBL] [Abstract][Full Text] [Related]
7. Management of the febrile neutropenic patient.
Picazo JJ;
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S120-2; discussion S133-40. PubMed ID: 16243492
[TBL] [Abstract][Full Text] [Related]
8. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
9. Cefepime monotherapy for treatment of febrile neutropenia in children.
Ariffin H; Ai CL; Lee CL; Abdullah WA
J Paediatr Child Health; 2006 Dec; 42(12):781-4. PubMed ID: 17096713
[TBL] [Abstract][Full Text] [Related]
10. Monotherapy for empiric treatment of fever in granulocytopenic cancer patients.
Wade JC; Johnson DE; Bustamante CI
Am J Med; 1986 May; 80(5C):85-95. PubMed ID: 3521273
[TBL] [Abstract][Full Text] [Related]
11. [Value of mono-antibiotic therapy using piperacillin associated with sulbactam and possibly followed by vancomycin in febrile neutropenia in solid tumors].
Abs L; Kattan J; Culine S; Bekradda M; Farhat F; Droz JP
Bull Cancer; 1994 Oct; 81(10):871-6. PubMed ID: 7734770
[TBL] [Abstract][Full Text] [Related]
12. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
[TBL] [Abstract][Full Text] [Related]
13. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
Klastersky J
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
[TBL] [Abstract][Full Text] [Related]
14. [Bacterial infections in neutropenic patients with cancer].
Matysiak M
Przegl Lek; 2003; 60 Suppl 5():54-7. PubMed ID: 14575008
[TBL] [Abstract][Full Text] [Related]
15. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
[TBL] [Abstract][Full Text] [Related]
17. The management of febrile episodes in-neutropenic cancer.
Bishop JF; McLennan R; Whiteside MG
Med J Aust; 1977 Apr; 1(14):473-5. PubMed ID: 865367
[TBL] [Abstract][Full Text] [Related]
18. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
[TBL] [Abstract][Full Text] [Related]
19. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
[TBL] [Abstract][Full Text] [Related]
20. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
